Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: A systematic review and meta-analysis

Journal of Neuro-Oncology

Volumn 105, Issue 2, 2011, Pages 325-335

  Olson, Robert A ^a,b   Brastianos, Priscilla K ^b,c,d   Palma, David A ^b,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

High grade glioma; Meta analysis; MGMT; Predictive markers; Prognostic markers

Indexed keywords

BETA INTERFERON; CARBOPLATIN; CARMUSTINE; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMUSTINE; NITROSOUREA; TEMOZOLOMIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; EPIGENETICS; EVIDENCE BASED MEDICINE; GENE SILENCING; GENETIC ASSOCIATION; GENETIC MARKER; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MOLECULAR PATHOLOGY; NEUROSURGERY; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; EPIGENESIS, GENETIC; GLIOMA; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASM GRADING; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 82955233990     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0594-5     Document Type: Article

References (41)

1. WJ Curran Jr CB Scott J Horton JS Nelson AS Weinstein AJ Fischbach CH Chang M Rotman SO Asbell RE Krisch DF Nelson 1993 Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials J Natl Cancer Inst 85 704 710 10.1093/jnci/85.9.704 8478956 10.1093/jnci/85.9.704 (Pubitemid 23133591)
2. Olson R, Tyldesley S, Carolan H, Parkinson M, Chhanabhai T, McKenzie M (2010) Prospective comparison of the prognostic utility of the Mini Mental State Examination and the Montreal Cognitive Assessment in patients with brain metastases. Support Care Cancer. doi: 10.1007/s00520-010-1028-1
3. ME Hegi A Diserens T Gorlia M Hamou N de Tribolet M Weller JM Kros JA Hainfellner W Mason L Mariani JEC Bromberg P Hau RO Mirimanoff JG Cairncross RC Janzer R Stupp 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 10.1056/NEJMoa043331 15758010 10.1056/NEJMoa043331 1:CAS:528:DC%2BD2MXit1Wktro%3D (Pubitemid 40349502)
4. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Res 59 793 797 10029064 1:CAS:528:DyaK1MXht1Sjurk%3D (Pubitemid 29086728)
5. Hall EJ, Giaccia AJ (2006) Radiobiology for the radiologist. Lippincott Williams & Wilkins, Philadelphia
6. 6-methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction BMC Cancer 11 35 10.1186/1471-2407-11-35 21269507 10.1186/1471-2407-11-35
7. I Zawlik S Vaccarella D Kita M Mittelbronn S Franceschi H Ohgaki 2009 Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study Neuroepidemiology 32 21 29 10.1159/000170088 18997474 10.1159/000170088
8. 6-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea Chemotherapy 69 420 425 10.1002/(SICI)1097-0215(19961021)69:5<420::AID-IJC12>3.0.CO;2-6 1:CAS:528:DyaK28Xnt1KgtLk%3D (Pubitemid 26384114)
9. 6-methylguanine DNA methyltransferase in human cancer Oncogene 23 1 8 10.1038/sj.onc.1207316 14712205 10.1038/sj.onc.1207316 1:CAS:528:DC%2BD2cXovVKnsQ%3D%3D (Pubitemid 38142234)
10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine 151:W-65, W-94. doi: 10.1059/0003-4819-151-4-200908180-00136
11. DF Stroup JA Berlin SC Morton I Olkin GD Williamson D Rennie D Moher BJ Becker TA Sipe SB Thacker for the Meta-Analysis of Observational Studies in Epidemiology Group 2000 Meta-analysis of observational studies in epidemiology: a proposal for reporting JAMA 283 2008 2012 10.1001/jama.283.15.2008 10789670 10.1001/jama.283.15.2008 1:STN:280:DC%2BD3c3kvVGgsA%3D%3D (Pubitemid 30214957)
12. L Duchateau L Collette R Sylvester JP Pignon 2000 Estimating number of events from the Kaplan-Meier curve for incorporation in a literature-based meta-analysis: what you don't see you can't get! Biometrics 56 886 892 10985232 10.1111/j.0006-341X.2000.00886.x 1:STN:280:DC%2BD3M%2Fms1yhtA%3D%3D
13. S Michiels P Piedbois S Burdett N Syz L Stewart JP Pignon 2005 Meta-analysis when only the median survival times are known: a comparison with individual patient data results Int J Technol Assess Health Care 21 119 125 15736523 10.1017/S0266462305050154 (Pubitemid 40229377)
14. T Hirooka C Hamada I Yoshimura 2009 A note on estimating treatment effect for time-to-event data in a literature-based meta-analysis Methods Inf Med 48 104 112 10.3414/ME0535 19283306
15. T Gorlia MJ van den Bent ME Hegi RO Mirimanoff M Weller JG Cairncross E Eisenhauer K Belanger AA Brandes A Allgeier D Lacombe R Stupp 2008 Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3 Lancet Oncol 9 29 38 10.1016/S1470-2045(07)70384-4 18082451 10.1016/S1470-2045(07)70384-4
16. WG Hopkins 2007 A spreadsheet for deriving a confidence interval, mechanistic inference and clinical inference from a p value Sportscience 11 16 20
17. B Costa C Caeiro I Guimarães O Martinho T Jaraquemada I Augusto L Castro L Osório P Linhares M Honavar M Resende F Braga A Silva F Pardal J Amorim R Nabiço R Almeida C Alegria M Pires C Pinheiro E Carvalho JM Lopes P Costa M Damasceno RM Reis 2010 Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study Oncol Rep 23 1655 1662 10.3892/or-00000808 20428822 1:CAS:528:DC%2BC3cXmvFyqtrc%3D
18. JP Higgins SG Thompson 2002 Quantifying heterogeneity in a meta-analysis Stat Med 21 1539 1558 10.1002/sim.1186 12111919 10.1002/sim.1186 (Pubitemid 34746062)
19. 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas Clin Cancer Res 11 5167 5174 10.1158/1078-0432.CCR-05-0230 16033832 10.1158/1078-0432.CCR-05-0230 1:CAS:528:DC%2BD2MXmt12qtbg%3D (Pubitemid 41003702)
20. M Schaich L Kestel M Pfirrmann K Robel T Illmer M Kramer C Dill G Ehninger G Schackert D Krex 2009 A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients Ann Oncol 20 175 181 10.1093/annonc/mdn548 18687982 10.1093/annonc/mdn548 1:STN:280:DC%2BD1M%2Fns12hsg%3D%3D
21. AA Brandes E Franceschi A Tosoni V Blatt A Pession G Tallini R Bertorelle S Bartolini F Calbucci A Andreoli G Frezza M Leonardi F Spagnolli M Ermani 2008 MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2192 2197 10.1200/JCO.2007.14.8163 18445844 10.1200/JCO.2007.14.8163
22. Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, Kang SS, Park CS, Lee KH, Chae HJ (2009) The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 65:866-875; discussion 875. doi: 10.1227/01.NEU.0000357325.90347.A1
23. JL Clarke FM Iwamoto J Sul K Panageas AB Lassman LM DeAngelis A Hormigo CP Nolan I Gavrilovic S Karimi LE Abrey 2009 Randomized Phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma J Clin Oncol 27 3861 3867 10.1200/JCO.2008.20.7944 19506159 10.1200/JCO.2008.20.7944 1:CAS:528:DC%2BD1MXhtFaitrrJ
24. J Dunn A Baborie F Alam K Joyce M Moxham R Sibson D Crooks D Husband A Shenoy A Brodbelt H Wong T Liloglou B Haylock C Walker 2009 Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy Br J Cancer 101 124 131 10.1038/sj.bjc.6605127 19536096 10.1038/sj.bjc.6605127 1:CAS:528:DC%2BD1MXotVKgtLk%3D
25. 6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival Clin Cancer Res 13 2606 2613 10.1158/1078-0432.CCR-06-2184 17473190 10.1158/1078-0432.CCR-06-2184 1:CAS:528:DC%2BD2sXkslOhtb4%3D (Pubitemid 46788026)
26. J Felsberg M Rapp S Loeser R Fimmers W Stummer M Goeppert HJ Steiger B Friedensdorf G Reifenberger MC Sabel 2009 Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients Clin Cancer Res 15 6683 6693 10.1158/1078-0432.CCR-08-2801 19861461 10.1158/1078-0432.CCR-08- 2801 1:CAS:528:DC%2BD1MXhtlCjsrfP
27. ER Gerstner S Yip DL Wang DN Louis AJ Iafrate TT Batchelor 2009 MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma Neurology 73 1509 1510 10.1212/WNL.0b013e3181bf9907 19884580 10.1212/WNL.0b013e3181bf9907 1:STN:280:DC%2BD1MjjsVKisw%3D%3D
28. M Glas C Happold J Rieger D Wiewrodt O Bahr JP Steinbach W Wick R Kortmann G Reifenberger M Weller U Herrlinger 2009 Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide J Clin Oncol 27 1257 1261 10.1200/JCO.2008.19.2195 19188676 10.1200/JCO.2008.19.2195 1:CAS:528:DC%2BD1MXktFKhsLk%3D
29. ME Hegi A Diserens S Godard P Dietrich L Regli S Ostermann P Otten G Van Melle N de Tribolet R Stupp 2004 Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin Cancer Res 10 1871 1874 10.1158/1078-0432.CCR-03-0384 15041700 10.1158/1078-0432.CCR-03-0384 1:CAS:528:DC%2BD2cXisVGltbY%3D (Pubitemid 38375541)
30. 6-methylguanine- deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy Neurosurgery 54 349 357 14744281 10.1227/01.NEU.0000103422.51382.99 discussion 357 (Pubitemid 38209403)
31. 6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods J Neurooncol 97 311 322 10.1007/s11060-009-0031-1 19841865 10.1007/s11060-009-0031-1 1:CAS:528:DC%2BC3cXltFOnsLw%3D
32. 6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort Cancer 115 4783 4794 10.1002/cncr.24546 19637364 10.1002/cncr.24546 1:CAS:528:DC%2BD1MXhtlGns7nK
33. CK Park SH Park SH Lee CY Kim DW Kim SH Paek DG Kim DS Heo IH Kim HW Jung 2009 Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin Neuropathology 29 443 449 10.1111/j.1440-1789.2008.00998.x 19170894 10.1111/j.1440-1789.2008.00998.x
34. AL Rivera CE Pelloski MR Gilbert H Colman C De La Cruz EP Sulman BN Bekele KD Aldape 2010 MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma Neuro Oncol 12 116 121 10.1093/neuonc/nop020 20150378 1:CAS:528:DC%2BC3cXotFKitb8%3D
35. R Stupp ME Hegi WP Mason MJ van den Bent MJ Taphoorn RC Janzer SK Ludwin A Allgeier B Fisher K Belanger P Hau AA Brandes J Gijtenbeek C Marosi CJ Vecht K Mokhtari P Wesseling S Villa E Eisenhauer T Gorlia M Weller D Lacombe JG Cairncross RO Mirimanoff European Organisation for Research, Treatment of Cancer Brain Tumour, Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459 466 10.1016/S1470-2045(09)70025-7 19269895 10.1016/S1470-2045(09)70025-7 1:CAS:528:DC%2BD1MXlsVKhs74%3D
36. 6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course Int J Cancer 113 581 587 10.1002/ijc.20625 15455376 10.1002/ijc.20625 1:CAS:528:DC%2BD2MXms1Gh (Pubitemid 40038734)
37. M Weller J Felsberg C Hartmann H Berger JP Steinbach J Schramm M Westphal G Schackert M Simon JC Tonn O Heese D Krex G Nikkhah T Pietsch O Wiestler G Reifenberger A von Deimling M Loeffler 2009 Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network J Clin Oncol 27 5743 5750 10.1200/JCO.2009.23.0805 19805672 10.1200/JCO.2009.23. 0805 1:CAS:528:DC%2BC3cXhtVWisbg%3D
38. M Esteller 2006 Epigenetics provides a new generation of oncogenes and tumour-suppressor genes Br J Cancer 94 179 183 10.1038/sj.bjc.6602918 16404435 10.1038/sj.bjc.6602918 1:CAS:528:DC%2BD28XmvVygtA%3D%3D (Pubitemid 43151531)
39. 6-alkylguanine-DNA alkyltransferase Prog Nucleic Acid Res Mol Biol 51 167 223 7659775 10.1016/S0079-6603(08)60879-X 1:CAS:528:DyaK2MXos1ertL0%3D
40. Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, Konduri SD (2010) Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol. doi: 10.1093/neuonc/noq044
41. 6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma J Clin Oncol 27 1262 1267 10.1200/JCO.2008.18.8417 19204199 10.1200/JCO.2008.18.8417 1:CAS:528:DC%2BD1MXktFKhsLY%3D